Study of Cisplatin in Cervical Cancer Stage IVB

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by Chinese Anti-Cancer Association.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Chinese Anti-Cancer Association
ClinicalTrials.gov Identifier:
NCT00826891
First received: January 16, 2009
Last updated: January 20, 2009
Last verified: January 2009

January 16, 2009
January 20, 2009
February 2009
January 2010   (final data collection date for primary outcome measure)
Response rate (CR + PR) (RECIST) [ Time Frame: 4~6 weeks after the end of treatment ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00826891 on ClinicalTrials.gov Archive Site
Toxicity [NCI CTCAE (Version 3.0)] [ Time Frame: 4~6 weeks after the end of treatment ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Study of Cisplatin in Cervical Cancer Stage IVB
Phase II Study of Cisplatin Combined With Topotecan in Advanced (Stage IVB) Recurrent or Persistent Cervical Cancer

This is a single arm, open-label study in women from China who have Advanced (stage IVB) Recurrent or Persistent cervical cancer to ⑴assess the response rate (i.e., CR + PR) of Cisplatin combined with Topotecan in treatment of advanced (stage IVB) recurrent or persistent Cervical cancer; ⑵assess the toxicities of CT regimen in treatment of cervical cancer. Prior to treatment, written informed consent should be obtained from all patients. Eligible patients will be assigned to CT regimen. The CT regimen is topotecan 0.75 mg/m2 IV during 30minutes days 1, 2, and 3; followed by cisplatin 50 mg/m2 IV on day1, repeated every 21 days. The study will consist of two phases: the safety run-in phase and study phase.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Cervical Cancer
Drug: Cisplatin Combined With Topotecan

Patients must have specific minimum neutrophil and platelet counts before administration of Hycamtin. The dose of Hycamtin is 0.75 mg/m2 by intravenous infusion over 30 minutes daily on days 1, 2, and 3; followed by cisplatin 50 mg/m2 by intravenous infusion on day 1 repeated every 21 days (a 21-day course).

Dosage adjustments for subsequent courses of Hycamtin in combination with cisplatin are specific for each drug.

Dose levels for cisplatin Initial dose 0 = 50 mg/m2 Dose reduction level -1 = 37.5 mg/m2 Dose reduction level -2 = 25 mg/m2

Dose levels for topotecan Initial dose 0 = 0.75 mg/m2 Dose reduction level -1 = 0.60 mg/m2 Dose reduction level -2 = 0.45 mg/m2

Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
40
January 2010
January 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • women with advanced recurrent or persistent carcinoma of the uterine cervical who were unsuitable candidates for curative treatment with surgery and/or radiotherapy.
  • Histologic types included squamous, adenosquamous, and adenocarcinoma of the cervia.
  • Patients must be at least 18 years old.
  • Measurable and/or evaluable disease parameters will be documented and recorded using clinical evaluation (and using CT for pathologic nodes when present).
  • Life expectation greater than 3 months.
  • Patients must have adequate organ function.
  • Patients without history of sensitivity to camptothecin or platinum.
  • Patients who are non-child-bearing potential, or consistent and correct use of methods of birth control from 2 weeks prior to administration of the first dose of study medication until 28 days after the final dose of observational medication.
  • performance status 0 to 2; to have recovered from the effects of recent surgery, chemoradiotherapy, or radiotherapy; and to be free of clinically significant infection.
  • Written informed consent

Exclusion Criteria:

  • Patients with uncontrolled infections.
  • Patients with concurrent severe medical problems unrelated to the malignancy which would expose the patient to extreme risk.
  • Patients who received another investigational drug within 30 days prior to study entry.
  • Patients who are receiving concurrent other chemotherapy, hormonal, immunotherapy or radiotherapy. Radiotherapy for palliation of related bone metastases is permitted.
  • Patients with a history of allergic reactions to compounds chemically related to topotecan or platinum.
  • Patients who are pregnant or lactating
  • Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin.
Both
18 Years and older
No
Not Provided
 
NCT00826891
CACA-2008-GSK1
No
xuan guo, Chinese Anti-Cancer Association
Chinese Anti-Cancer Association
Not Provided
Not Provided
Chinese Anti-Cancer Association
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP